Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD039
MIFTS: 39

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Adenocarcinoma

About this section

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 74
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 56

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3711
NCIt 51 C39836 C4032
UMLS 74 C0279682
Sources

Summaries for Bladder Adenocarcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to clear cell adenocarcinoma and mammary paget's disease, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and colon, and related phenotype is neoplasm.

Sources

Related Diseases for Bladder Adenocarcinoma

About this section

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 30.2 KRT20 KRT7
2 mammary paget's disease 29.7 KRT20 KRT7
3 mucinous adenocarcinoma 29.5 CDX2 KRT20 KRT7
4 appendix adenocarcinoma 29.3 CDX2 KRT20 KRT7
5 signet ring cell adenocarcinoma 29.3 CDX2 KRT20 KRT7
6 transitional cell carcinoma 29.1 HRAS KRT20 KRT7
7 glandular cystitis 29.1 CDX2 KRT20 KRT7 UCA1
8 endometrial cancer 29.1 CTNNB1 HRAS KRT7 UCA1
9 colorectal adenocarcinoma 28.3 CDX2 CTNNB1 HRAS KRT20 KRT7
10 lung cancer susceptibility 3 28.3 CDX2 CTNNB1 HRAS KRT20 KRT7
11 bladder signet ring cell adenocarcinoma 11.5
12 pelvic lipomatosis 11.2
13 bladder clear cell adenocarcinoma 11.2
14 bladder colloid adenocarcinoma 11.1
15 bladder colonic type adenocarcinoma 11.1
16 bladder urachal adenocarcinoma 11.1
17 bladder tubulo-cystic clear cell adenocarcinoma 11.1
18 bladder papillary clear cell adenocarcinoma 11.1
19 bladder hepatoid adenocarcinoma 11.1
20 adenocarcinoma 10.5
21 gallbladder adenoma 10.3 CTNNB1 HRAS
22 goblet cell carcinoid 10.2 CTNNB1 KRT20
23 hepatoid adenocarcinoma 10.2
24 skin squamous cell carcinoma 10.1 FBXW7 HRAS
25 serous cystadenocarcinoma 10.1 FBXW7 HRAS
26 vaginal benign neoplasm 10.1 CDX2 KRT20
27 vaginal adenoma 10.1 CDX2 KRT20
28 vaginal tubulovillous adenoma 10.1 CDX2 KRT20
29 villous adenoma 10.1 CDX2 KRT20
30 colorectal adenoma 10.1 CTNNB1 HRAS
31 cystitis 10.1
32 skin benign neoplasm 10.1 HRAS KRT20
33 papillary craniopharyngioma 10.0 CTNNB1 KRT7
34 craniopharyngioma 10.0 CTNNB1 KRT7
35 uterine carcinosarcoma 10.0 CTNNB1 FBXW7 HRAS
36 adenomyoma 10.0 CTNNB1 KRT7
37 female reproductive endometrioid cancer 10.0 CTNNB1 KRT7
38 pulmonary sclerosing hemangioma 10.0 CTNNB1 KRT7
39 sclerosing hemangioma 10.0 CTNNB1 KRT7
40 tubular adenocarcinoma 10.0 CDX2 KRT20
41 ovarian serous cystadenocarcinoma 10.0 FBXW7 HRAS
42 acinar cell carcinoma 10.0 CTNNB1 KRT7
43 cystadenoma 10.0 KRT20 KRT7
44 cystic basal cell carcinoma 10.0 KRT20 KRT7
45 prostate squamous cell carcinoma 10.0 HRAS KRT7
46 seminal vesicle adenocarcinoma 10.0 KRT20 KRT7
47 transverse colon cancer 10.0 KRT20 KRT7
48 malignant syringoma 10.0 KRT20 KRT7
49 papillary transitional carcinoma 10.0 KRT20 KRT7
50 eyelid carcinoma 10.0 KRT20 KRT7

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma
Sources

Symptoms & Phenotypes for Bladder Adenocarcinoma

About this section

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDX2 CTNNB1 FBXW7 HRAS
Sources

Drugs & Therapeutics for Bladder Adenocarcinoma

About this section

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 interferons Phase 3
5 Anti-Bacterial Agents Phase 3,Phase 1
6 Antiviral Agents Phase 3,Phase 2
7 Vaccines Phase 3,Phase 1
8 Anti-Infective Agents Phase 3,Phase 2,Phase 1
9 Adjuvants, Immunologic Phase 3
10 Interferon-alpha Phase 3
11 Mitomycins Phase 3
12 Immunologic Factors Phase 3,Phase 2,Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 3
14 Topoisomerase Inhibitors Phase 3,Phase 2
15 Alkylating Agents Phase 3,Phase 2
16 Antibiotics, Antitubercular Phase 3
17 Pharmaceutical Solutions Phase 3
18 Antimetabolites, Antineoplastic Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20 Antimetabolites Phase 3,Phase 2
21
leucovorin Approved Phase 2 58-05-9 6006 143
22
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
23
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
24
Ifosfamide Approved Phase 2 3778-73-2 3690
25
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
nivolumab Approved Phase 2,Phase 1 946414-94-4
28
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
29
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
30
Gemcitabine Approved Phase 2 95058-81-4 60750
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
33 Piritrexim Investigational Phase 2 72732-56-0
34
Camptothecin Experimental Phase 2 7689-03-4
35
Rubitecan Investigational Phase 2 91421-42-0
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Vitamin B Complex Phase 2
38 Vitamin B9 Phase 2
39 Folate Phase 2
40 Folic Acid Antagonists Phase 2
41 topoisomerase I inhibitors Phase 2
42 Albumin-Bound Paclitaxel Phase 2
43 Antimitotic Agents Phase 2
44 Antineoplastic Agents, Phytogenic Phase 2
45 Antineoplastic Agents, Alkylating Phase 2
46
Isophosphamide mustard Phase 2 0
47 Immunoglobulins Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 2,Phase 1
49 Antibodies Phase 2,Phase 1
50 Antineoplastic Agents, Immunological Phase 2,Phase 1

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
5 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
6 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
7 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
8 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
9 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
10 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
11 Cabozantinib S-Malate, Nivolumab, and Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Not yet recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
12 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
13 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
14 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
15 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
16 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
17 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
18 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Sources

Genetic Tests for Bladder Adenocarcinoma

About this section
Sources

Anatomical Context for Bladder Adenocarcinoma

About this section

MalaCards organs/tissues related to Bladder Adenocarcinoma:

42
Liver, Lung, Colon
Sources

Publications for Bladder Adenocarcinoma

About this section

Articles related to Bladder Adenocarcinoma:

(show all 36)
# Title Authors Year
1
Primary bladder adenocarcinoma: Case report with long-term follow-up. ( 29785373 )
2018
2
Treating bladder adenocarcinoma. ( 30687599 )
2018
3
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. ( 28511402 )
2017
4
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. ( 28548125 )
2017
5
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. ( 27006847 )
2016
6
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. ( 27427223 )
2016
7
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. ( 26955660 )
2016
8
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. ( 27048257 )
2016
9
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. ( 27288750 )
2016
10
Gall bladder Adenocarcinoma in a Young Girl. ( 26139973 )
2015
11
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. ( 26421206 )
2015
12
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. ( 24716732 )
2014
13
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. ( 25040620 )
2014
14
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. ( 24596525 )
2013
15
Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. ( 24281125 )
2013
16
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. ( 23589601 )
2013
17
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. ( 23076693 )
2012
18
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. ( 23121893 )
2012
19
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. ( 22294067 )
2011
20
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. ( 22081531 )
2011
21
Association of bladder adenocarcinoma and BK virus infection in a pancreatico-renal transplant recipient. ( 28657060 )
2010
22
Bladder adenocarcinoma following gastrocystoplasty. ( 20392671 )
2010
23
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. ( 19221283 )
2009
24
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. ( 18604226 )
2008
25
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. ( 18307003 )
2008
26
Urinary bladder adenocarcinoma arising in a spina bifida patient. ( 18022132 )
2007
27
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. ( 15822823 )
2005
28
Spontaneous resolution of bladder adenocarcinoma. ( 15160537 )
2003
29
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. ( 19861819 )
2003
30
Bladder adenocarcinoma: 31 reported cases. ( 11718635 )
2001
31
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. ( 11506474 )
2001
32
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. ( 10510893 )
1999
33
Urine cytology of primary and secondary urinary bladder adenocarcinoma. ( 9915134 )
1998
34
Bladder adenocarcinoma during pregnancy: a case report. ( 8855078 )
1996
35
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. ( 8389497 )
1993
36
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). ( 6983292 )
1982
Sources

Variations for Bladder Adenocarcinoma

About this section
Sources

Expression for Bladder Adenocarcinoma

About this section
Search GEO for disease gene expression data for Bladder Adenocarcinoma.
Sources

Pathways for Bladder Adenocarcinoma

About this section

Pathways related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases 23
Show member pathways
 11.99 CDX2 CTNNB1 HRAS
2
Pathways Affected in Adenoid Cystic Carcinoma 1
11.14 FBXW7 HRAS
3
TGF-beta Receptor Signaling (WikiPathways) 1
10.92 CTNNB1 HRAS
4
Incretin synthesis, secretion, and inactivation 67
Show member pathways
 10.7 CDX2 CTNNB1
5
Extracellular vesicle-mediated signaling in recipient cells 1
10.1 CTNNB1 HRAS
Sources

GO Terms for Bladder Adenocarcinoma

About this section

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.16 CTNNB1 FBXW7
2 negative regulation of gene expression GO:0010629 9.13 CTNNB1 FBXW7 HRAS
3 vasculature development GO:0001944 8.62 CTNNB1 FBXW7
Sources

Sources for Bladder Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....